GENB AS |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.22 USD | +44.51% |
|
+0.50% | +10.11% |
| Sales 2024 * | 19.81B 2.84B | Sales 2025 * | 23.61B 3.39B | Capitalization | 117B 16.8B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.67B 670M | Net income 2025 * | 6.54B 938M | EV / Sales 2024 * | 4.61 x |
| Net cash position 2024 * | 25.89B 3.71B | Net cash position 2025 * | 32.22B 4.62B | EV / Sales 2025 * | 3.6 x |
| P/E ratio 2024 * |
26.8
x | P/E ratio 2025 * |
19.5
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on GENB AS
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
| Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +18.84% | 124B | |
| +17.85% | 111B | |
| -11.74% | 23.17B | |
| +5.07% | 22.94B | |
| -39.94% | 17.42B | |
| -10.48% | 17.42B | |
| +2.71% | 13.71B | |
| +25.84% | 11.82B | |
| +103.58% | 9.94B |
